American Registry of Ambulatory or acutely decompensated heart failure (AMERICCAASS Registry): First 1000 patients.

BACKGROUND: About 80% of cardiovascular diseases (including heart failure [HF]) occur in low-income and developing countries. However, most clinical trials are conducted in developed countries. HYPOTHESIS: The American Registry of Ambulatory or Acutely Decompensated Heart Failure (AMERICCAASS) aims to describe the sociodemographic characteristics of HF, comorbidities, clinical presentation, and pharmacological management of patients with ambulatory or acutely decompensated HF in America. METHODOLOGY: Descriptive, observational, prospective, and multicenter registry, which includes patients >18 years with HF in an outpatient or hospital setting. Collected information is stored in the REDCap electronic platform. Quantitative variables are defined according to the normality of the variable using the Shapiro-Wilk test. RESULTS: This analysis includes data from the first 1000 patients recruited. 63.5% were men, the median age of 66 years (interquartile range 56.7-75.4), and 77.6% of the patients were older than 55 years old. The percentage of use of the four pharmacological pillars at the time of recruitment was 70.7% for beta-blockers (BB), 77.4% for angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB II)/angiotensin receptor-neprilysin inhibitor (ARNI), 56.8% for mineralocorticoid receptor antagonists (MRA), and 30.7% for sodium-glucose cotransporter type-2 inhibitors (SGLT2i). The main cause of decompensation in hospitalized patients was HF progression (64.4%), and the predominant hemodynamic profile was wet-warm (68.3%). CONCLUSIONS: AMERICCAASS is the first continental registry to include hospitalized or outpatient patients with HF. Regarding optimal medical therapy, approximately a quarter of the patients still need to receive BB and ACEI/ARB/ARNI, less than half do not receive MRA, and more than two-thirds do not receive SGLT2i.

Valor del poder cardíaco como factor pronóstico en pacientes postoperados de cirugía de revascularización coronario / Value of cardiac power as a prognostic factor in postoperative coronary artery bypass graft surgery patients

Se investigó la utilidad del poder cardíaco como unaherramienta más para determinar si existe algúnimpacto en la sobrevida en aquellos pacientes queson sometidos a cirugía de revascularizacióncoronaria bajo circulación extracorpórea.la fase pre-quirúrgica, la media del poder1Objetivos: Determinar si el poder cardíaco es unfactor pronóstico de morbilidad, mortalidad yeventos cardiovasculares mayores en el postoperatorioinmediato de cirugía de revascularización coronariabajo circulación extracorpórea. Métodos: Estudio retrospectivo,descriptivo y transvesal en una serie decasos. Resultados: Se analizaron 59 pacientes. Encardíaco fue de 0.78 watts, con una desviaciónestándar de 0.25. En fase postquirúrgica inmediatael poder cardíaco promedio fue 0.84 watts. En el15% éste fue menor de 0.7 watts a las 12 horas; el 62%de estos tuvo una estancia hospitalaria mayorde 3 días asociada a complicaciones cardíacas. Conclusiones:Un poder cardíaco igual omayor de 0.7 watt a 12 horas del postoperatoriopredice una evaluación favorable a corto plazo,con una alta especificidad (94%), sin eventosadversos, y una menor estancia hospitalaria...